Lobectomy in patients with differentiated thyroid cancer: experience of a Chilean tertiary center

Ignacio Fuentes, Roberto Santana, Martin Espinoza,Eugenio Arteaga,Thomas Uslar,Rene Baudrand,Gilberto González,Francisco J. Guarda,Nicole Lustig,Lorena Mosso,Flavia Nilo,Felipe Valenzuela,Francisco Domínguez, Hernán Eugenio González,Pablo H. Montero,Francisco Cruz,Antonieta Solar,José M. Domínguez

Endocrine（2024）

引用 0|浏览8

暂无评分

摘要

Thyroid lobectomy (TL) is an appropriate treatment for up to 4 cm intrathyroidal differentiated thyroid cancer (DTC). There is scarce data regarding TL outside first-world centers. Our aim is to report a cohort of patients with DTC treated with TL in Chile. We included DTC patients treated with TL, followed for at least 6 months, characterized their clinicopathological features and classified their risk of recurrence and response to treatment. Eighty-two patients followed for a median of 2.3 years (0.5–7.0). Seventy-three (89

查看译文

关键词

Thyroid cancer,Lobectomy,Anti thyroglobulin antibodies,Quality of Life,Personalized medicine

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要